Akums Drugs and Pharmaceuticals Limited (MAINBOARD)
Jul 30, 2024 - Aug 1, 2024
| Price | ₹646 - ₹679 |
| Premium | ₹43 |
|---|---|
| Lot size | 22 |
| Allotment | Aug 2, 2024 |
| Listing | Aug 6, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 22 | 14938 | 123292 |
| sHNI | 14 | 308 | 209132 | 4403 |
| bHNI | 67 | 1474 | 1000846 | 8807 |
Last updated on 01-Aug-2024 18:45:06
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 8137276 | 733117770 | 90.09 |
| HNIs | 4068637 | 171750128 | 42.21 |
| HNIs 10+ | 2712424 | 128649664 | 47.43 |
| HNIs 2+ | 1356212 | 43100464 | 31.78 |
| Retail | 2712424 | 57770020 | 21.3 |
| Employees | 243902 | 1041216 | 4.27 |
| Total | 15162239 | 963679134 | 63.56 |
Application Wise Breakup (Approx) | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 8807 | 84932 | 9.64 |
| HNIs (2-10L) | 4403 | 135305 | 30.73 |
| Retail | 123292 | 2104030 | 17.07 |
| Total Applications: 2395516 | |||
| © IPO Premium | |||
| QIB Interest Cost per share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹82.12 | @8% ₹93.85 | @9% ₹105.58 | @10% ₹117.31 | @11% ₹129.05 | @12% ₹140.78 |
Akums Drugs and Pharmaceuticals IPO Details
| Issue Size | 27,345,162 shares (aggregating up to ₹1,856.74 Cr) |
| Fresh Issue | 10,014,727 shares (aggregating up to ₹680.00 Cr) |
| Offer for Sale | 17,330,435 shares of ₹2 (aggregating up to ₹1,176.74 Cr) |
| Employee Discount | Rs 64 per share |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 147,356,280 |
| Share holding post issue | 157,371,007 |
Akums Drugs and Pharmaceuticals IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not less than 75.00% of the Net offer |
| Retail Shares Offered | Not more than 10.00% of the Offer |
| NII (HNI) Shares Offered | Not less than 15.00% of the Offer |
Key Performance Indicator
| KPI | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|
| ROE | 0.11% | 13.52% | -40.13% |
| ROCE | 3.37% | 24.60% | -18.89% |
| RONW | -0.57% | 13.23% | -40.60% |
| D/E | 0.69 | 0.75 | 0.58 |
| EPS (basic) | 0.28 | 6.63 | -17.65 |
Company Financials
Akums Drugs and Pharmaceuticals Limited Financial Information (Restated Consolidated)
Akums Drugs and Pharmaceuticals Limited's revenue increased by 13.81% and profit after tax (PAT) dropped by -99.19% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.50 | 717.19 | 621.98 |
| Reserves | 861.01 | 868.70 | 787.79 |
| Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore | |||
About Company
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a prominent pharmaceutical contract development and manufacturing organization (CDMO) offering comprehensive solutions for product development, manufacturing, and R&D of formulations. The company specializes in preparing and submitting regulatory dossiers for both Indian and global markets, along with providing various testing services. Additionally, Akums is involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs). The company boasts a diverse manufacturing portfolio, producing tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears, among others. With an impressive record of 4,025 commercialized formulations across over 60 dosage forms, Akums served 26 of the top 30 pharmaceutical companies in India by revenue in FY 2023. Operating 10 manufacturing units with a cumulative capacity of 49.21 billion units annually as of September 30, 2023, the company plans to expand with two additional production units by FY 2025. Several of its facilities hold accreditations from global regulatory bodies like EU-GMP, WHO-GMP, and US NSF. As of September 30, 2023, Akums employed 16,463 people, including 7,211 full-time and 9,252 contract employees.
ICICI Securities Limited
Axis Bank Limited
Citigroup Global Markets India Private Limited
Ambit Private Limited
Market Leadership: Akums Drugs and Pharmaceuticals Limited is the largest India-focused CDMO serving the Indian domestic pharmaceutical industry (Source: F&S Report).
Diverse Client Base: The Company has a broad and longstanding client base with strong CDMO relationships, including manufacturing for 26 of the top 30 pharmaceutical companies in India by revenue in FY 2023.
R&D Capabilities: Akums boasts large and rapidly growing R&D capabilities across its extensive product portfolio, enhancing its innovation and development processes.
Geographic Concentration: With manufacturing units and R&D centers concentrated in Haridwar, Uttarakhand, Akums faces risks from economic, regulatory, political changes, and natural disasters in this region, potentially impacting business operations and financial health.
Operational Disruptions: Any slowdown or shutdown of manufacturing and R&D operations could negatively affect Akums' business, results, financial condition, and cash flows.
Regulatory Compliance: Periodic inspections and audits by regulatory authorities and clients may lead to regulatory actions, which could harm Akums' reputation and adversely affect its business, results, financial condition, and cash flows.
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: akumsdrugs.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html